Press releases

Beactica awarded €0.7 million from EU for pioneering influenza research

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has received a grant of up to €700 000 from the EU 7th Framework Programme to support the Company’s pioneering work in the area of influenza. In the FluCure project, Beactica will apply its proprietary fragment-based... [...]

Beactica announces the appointment of a new Chairman and a new Member to its Board

Uppsala, Sweden, December 14th, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced that board member Gisela Sitbon will assume the position of Chairman and that Mr Jan Mellberg will join its Board, both effective immediately. Dr Gisela Sitbon has more than 25 years experience... [...]

Beactica appoints Dr Evert Homan as Chief Operating Officer

Uppsala, Sweden, September 3rd, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced the promotion of Dr Evert Homan to Chief Operating Officer. Evert has been with the Company since 2008 when he joined from Biovitrum. He has more than ten years experience from the international... [...]

Beactica awarded grant for pioneering brain research

Uppsala, Sweden, August 9th, 2010 Beactica, the Swedish fragment-based drug discovery company, today announced its participation in a European expertise network that will address human brain disease. The network, called SynSys, has been awarded funding through the 7th EU Framework Programme and aims to achieve... [...]

Dr Gisela Sitbon joins the Board of Beactica

Uppsala, Sweden, February 3rd, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced the appointment of Dr Gisela Sitbon to its Board. Dr Sitbon, Deputy Region Director at Innovationsbron AB, brings more than 25 years experience from the life science industry within the areas... [...]

Beactica welcomes Innovationsbron as a new shareholder

Uppsala, Sweden, January 29th, 2010 Beactica AB, the leading Swedish fragment-based drug discovery company, today announced a new investment and the addition of Innovationsbron AB to its shareholders. They join Uppsala University Holding Company and the founders as continuing investors. The funds will be used to... [...]

Professor Bo Öberg joins the Board of Beactica

Uppsala, Sweden, January 13th, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced the appointment of Professor Bo Öberg to its Board. Professor Öberg, CEO of Medivir HIV Franchise AB, brings almost 40 years of pharmaceutical industry experience as a senior executive and board... [...]